To evaluate patient-reported health-related quality-of-life (QoL) in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) advanced/metastatic breast cancer (ABC) treated with palbociclib in the longitudinal real-world study, POLARIS. This evidence concerns the gene ERBB2 and aneurysmal bone cyst.